Suggested remit: To appraise the clinical and cost effectiveness of benralizumab with corticosteroids within its marketing authorisation for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6266

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6266 16 July 2024 - 13 August 2024

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 July 2024 In progress. Scoping commencing
17 May 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2024 when we will write to you about how you can get involved.
18 January 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
18 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual